JPS63145233A - 白内障治療剤 - Google Patents
白内障治療剤Info
- Publication number
- JPS63145233A JPS63145233A JP29154286A JP29154286A JPS63145233A JP S63145233 A JPS63145233 A JP S63145233A JP 29154286 A JP29154286 A JP 29154286A JP 29154286 A JP29154286 A JP 29154286A JP S63145233 A JPS63145233 A JP S63145233A
- Authority
- JP
- Japan
- Prior art keywords
- cataract
- lens
- calcium
- vitamin
- dihydroxyvitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002177 Cataract Diseases 0.000 title claims abstract description 24
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 14
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 14
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 14
- 239000011710 vitamin D Substances 0.000 claims abstract description 14
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 14
- 229940046008 vitamin d Drugs 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 6
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 3
- FCKJYANJHNLEEP-OIMXRAFZSA-N 24,25-Dihydroxyvitamin D Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C FCKJYANJHNLEEP-OIMXRAFZSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 abstract description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 12
- 229910052791 calcium Inorganic materials 0.000 abstract description 12
- 230000005856 abnormality Effects 0.000 abstract description 4
- 206010007749 Cataract diabetic Diseases 0.000 abstract description 2
- 201000007025 diabetic cataract Diseases 0.000 abstract description 2
- 201000008525 senile cataract Diseases 0.000 abstract description 2
- 210000000695 crystalline len Anatomy 0.000 description 16
- 238000011282 treatment Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 229920000818 Catalin Polymers 0.000 description 1
- 206010007747 Cataract congenital Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241001575108 Latipes Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OKPNYGAWTYOBFZ-UHFFFAOYSA-N Pirenoxine Chemical compound C12=NC3=CC=CC=C3OC2=CC(=O)C2=C1C(=O)C=C(C(=O)O)N2 OKPNYGAWTYOBFZ-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 208000022458 calcium metabolism disease Diseases 0.000 description 1
- XFQYJNINHLZMIU-UHFFFAOYSA-N cataline Natural products CN1CC(O)C2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 XFQYJNINHLZMIU-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29154286A JPS63145233A (ja) | 1986-12-09 | 1986-12-09 | 白内障治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29154286A JPS63145233A (ja) | 1986-12-09 | 1986-12-09 | 白内障治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63145233A true JPS63145233A (ja) | 1988-06-17 |
| JPH0443887B2 JPH0443887B2 (OSRAM) | 1992-07-20 |
Family
ID=17770254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP29154286A Granted JPS63145233A (ja) | 1986-12-09 | 1986-12-09 | 白内障治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63145233A (OSRAM) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996029079A1 (en) * | 1995-03-20 | 1996-09-26 | Katsuhiko Mukai | Ophthalmological composition comprising activated vitamin d |
| WO1997018817A1 (en) * | 1995-11-20 | 1997-05-29 | Kiyoshi Kita | External preparation containing vitamin d or vitamin k |
| WO1998053806A1 (en) * | 1997-05-26 | 1998-12-03 | New Vision Co., Ltd. | Medicinal compositions for topical administration containing vitamin d and vitamin k |
| US6187331B1 (en) | 1997-06-10 | 2001-02-13 | New Vision Co., Ltd. | Composition for prophylaxis and/or treatment of dry syndrome comprising vitamin D |
-
1986
- 1986-12-09 JP JP29154286A patent/JPS63145233A/ja active Granted
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996029079A1 (en) * | 1995-03-20 | 1996-09-26 | Katsuhiko Mukai | Ophthalmological composition comprising activated vitamin d |
| US6500813B1 (en) | 1995-03-20 | 2002-12-31 | Katsuhiko Mukai | Ophthalmic composition containing active vitamin D |
| WO1997018817A1 (en) * | 1995-11-20 | 1997-05-29 | Kiyoshi Kita | External preparation containing vitamin d or vitamin k |
| US6162801A (en) * | 1995-11-20 | 2000-12-19 | Kita; Kiyoshi | External ophthalmic preparation containing vitamin D |
| WO1998053806A1 (en) * | 1997-05-26 | 1998-12-03 | New Vision Co., Ltd. | Medicinal compositions for topical administration containing vitamin d and vitamin k |
| US6187331B1 (en) | 1997-06-10 | 2001-02-13 | New Vision Co., Ltd. | Composition for prophylaxis and/or treatment of dry syndrome comprising vitamin D |
| US6410006B2 (en) | 1997-06-10 | 2002-06-25 | New Vision Co., Ltd. | Composition for prophylaxis and/or treatment of dry eye syndrome comprising vitamin D |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0443887B2 (OSRAM) | 1992-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1238280A (en) | Pharmaceutical compositions containing bilobalid | |
| Albright et al. | A comparison of the effects of AT 10 (dihydrotachysterol) and vitamin D on calcium and phosphorus metabolism in hypoparathyroidism | |
| AU2007203159B2 (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone | |
| US4735967A (en) | Method for desensitizing the gastrointestinal tract from food allergies | |
| NO315968B1 (no) | Anvendelse av fumagillol og derivater derav for fremstilling av medikamenter mot tarminfeksjoner | |
| US20090142427A1 (en) | Composition and its Therapeutic Use | |
| US5393531A (en) | Process for the preparation of a pharmaceutical formulation containing at least two different active substances and use of such a formulation | |
| DE19858789A1 (de) | Kombination von Cerivastatin und Fibraten | |
| GB2110532A (en) | Bendazac compositions for treatment of cataract | |
| NZ504656A (en) | Substituted aminomethyl-chromans are used for the regenerative treatment of neurological conditions which are the sequelae of damage due to surgical intervention, exposure to toxic agents, infections, tumours, and other diseases and conditions | |
| JPH05194209A (ja) | 血管内皮細胞機能改善剤 | |
| JPS63145233A (ja) | 白内障治療剤 | |
| DE3202561A1 (de) | Lysinsalze der ((1-benzyl-1h-indazol-3-yl)-oxy)-essigsaeure, verfahren zu deren herstellung und diese enthaltende arzneimittel | |
| EP0569415A1 (en) | Pharmaceutical combination for the prevention and treatment of postmenopausal osteoporosis | |
| JPS6360940A (ja) | 白内障の予防または治療剤 | |
| EP0191520A1 (en) | (1-phenylmethyl-5-hydroxy-1H-indazol-3-yl)-oxyacetic acid and salts thereof for use as a medicament, and pharmaceutical compositions containing them | |
| EP0402208B1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique | |
| NZ203251A (en) | Pharmaceutical compositions containing 1alpha,25,26-trihydroxycholecalciferol | |
| US5486506A (en) | Method for treating cardiac inotropic irregularities | |
| CN105935443A (zh) | 一种治疗糖尿病性白内障的药物组合物 | |
| JP2807535B2 (ja) | 白内障治療剤 | |
| JPS63183534A (ja) | 乾癬治療剤 | |
| US4105794A (en) | Process of mitigating cholelithiasis | |
| De Roetth | Local Action of Oils Containing Vitamin A: Experimental Contribution | |
| US3773937A (en) | Method of treatment |